VivoSeq
Other

MODY

2

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

MODY is an early-stage landscape with 2 programs across 2 companies. The most active players are Sanofi, Novo Nordisk. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

67/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

ApprovedNovo Nordisk logo

Novo Nordisk

1 program

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved2

Glimepiride

Sanofi

Liraglutide

Novo Nordisk

Analysis

Modality Breakdown

2programs
Small molecule150%
Peptide150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

8

clinical trials

Unknown status4 · 50%
Completed2 · 25%
Terminated1 · 13%
Recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

Pharmacodynamic Analysis of the HaemOdynamic Effects of a Standard Fluid BolUS
Recruiting·—·N/A·NCT06839404·500 enrolled
The Potential Role for Adenosine in the Haemodynamic Effects of Free Fatty Acids
Completed·RRadboud University Medical Center·N/A·NCT00184899·20 enrolled
Impact of SGLT2 on Glucosuria in HNF1A-MODY
Completed·SSteno Diabetes Center Copenhagen·N/A·NCT05417646·21 enrolled
Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test.
Terminated·PPirogov Russian National Research Medical University·Phase 4·NCT04710732·9 enrolled
The Effect of Glyceryl Trinitate and Diamox on Cerebral Haemodynamics.
Unknown status·DDanish Headache Center·N/A·NCT00363571·12 enrolled
Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters
Unknown status·—·N/A·NCT02490176·50 enrolled
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin
Unknown status·—·Phase 2·NCT03449251·170 enrolled
Baseline Cortical Haemodynamics in MS
Unknown status·UUniversity of Nottingham·N/A·NCT02481882·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)